Skip to main content

Table 5 Best overall response a by TIMP-1 protein status b

From: TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

 

TIMP-1 Positive

TIMP-1 Negative

Response

No.

(%)

No.

(%)

CR

4

(3.0)

2

(6.3)

PR

46

(34.8)

9

(28.1)

Total responses

50

(37.9)

11

(34.4)

(95% CI)

(24.2 to 40.8)

  

(30.7 to 69.4)

SD

56

(42.4)

15

(46.9)

PD

15

(11.4)

5

(15.6)

Unknown

11

(8.3)

1

(3.1)

Total

132

 

32

 
  1. aMeasurable disease (n = 164).
  2. bTotal responses, Fisher's exact test P =0.84.
  3. Abbreviations: CI Confidence interval, CR Complete response, PD Progressive disease, PR Partial response, SD Stable disease, TIMP-1 Tissue inhibitor of metalloproteinases-1.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us